Humacyte (HUMA) Change in Account Payables (2020 - 2026)

Humacyte (HUMA) has reported Change in Account Payables for 7 consecutive years, with -$362000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Account Payables fell 155.44% year-over-year to -$362000.0; the TTM figure through Mar 2026 stood at -$42000.0 (down 102.56% YoY), while the FY2025 annual figure was $973000.0, up 149.59% from the prior year.
• Change in Account Payables grew to -$362000.0 in Q1 2026 per HUMA's latest filing, from -$4.2 million in the prior quarter.
• Across five years, Change in Account Payables topped out at $3.5 million in Q4 2023 and bottomed at -$4.2 million in Q4 2025.
• Historically, Change in Account Payables has averaged $173588.2 across 5 years, with a median of $526000.0 in 2023.
• Annual changes were most pronounced in 2022 — Change in Account Payables soared 5183.33% — and 2024, when it slumped 1086.29%.
• Humacyte's Change in Account Payables stood at -$1.5 million in 2022, then surged by 335.7% to $3.5 million in 2023, then sank by 169.25% to -$2.4 million in 2024, then tumbled by 70.74% to -$4.2 million in 2025, then jumped by 91.3% to -$362000.0 in 2026.
• Business Quant data shows HUMA's Change in Account Payables at -$362000.0 in Q1 2026, -$4.2 million in Q4 2025, and $3.0 million in Q3 2025.